David R Webb Email and Phone Number
David R Webb work email
- Valid
- Valid
David R Webb personal email
- Valid
David R Webb phone numbers
Dr. Webb is currently CEO of Rev-Therapeutics. He retired as CEO of Synbal, Inc. the Active Genetics Company in July 2023. In 2021 with a group of colleagues he formed Rev-Therapeutics to find and develop/repurpose drugs for unmet medical needs; he was also Chairman of the Board of Agragene (2018-2022) in addition to being Adjunct Professor in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute, where he has been since 2011. He joined Celgene-San Diego in September, 2003 as Vice President, Research and retired in June, 2011. During this time, the Research Division has placed six drugs into clinical development. Between 1995 and 2003, he held senior management positions in several biotechnology companies where he developed and led drug discovery programs focused on inflammation, asthma, cancer and diabetes. These included Syrrx, 2001-2003, as Vice President of Drug Discovery; OSI Pharmaceuticals (Corporate Vice President, Drug Discovery 1999-2001) and Cadus Pharmaceutical Corporation where he was Vice President of Research and Chief Scientific Officer from 1995 to 1999 and adjunct professor of Microbiology and Immunology at New York Medical College. From 1987 to 1995, Dr. Webb was at Syntex, Inc where he held the positions of Distinguished Scientist and Director, Institute of Immunology and Biological Sciences and was also Consulting Professor of Cancer Biology at Stanford University. Dr. Webb was a member of the Department of Cell Biology at the Roche Institute of Molecular Biology from 1973 to 1987 and was Adjunct Assoc. Professor of Human Genetics at Columbia University College of Physicians and Surgeons. He has published over 200 peer reviewed publications and has served on numerous editorial boards and study sections (NIH, NSF, VA) in Immunology. Dr. Webb received his Ph.D. from Rutgers University and was a Dernham Junior Fellow in Cancer Research at UCSF.Specialties: Drug Discovery and DevelopmentCRISPR/Cas9 based gene drive technology platformImmunology (autoimmunity, immune regulation, cell signaling)Oncology (Tumor immunology, cell signaling and metabolism)
-
Adjunct ProfessorThe Scripps Research InstituteSan Diego, Ca, Us
-
Chairman Of The BoardRev Therapeutics Oct 2020 - Present -
Adjunct ProfessorThe Scripps Research Institute May 2011 - PresentLa Jolla, California, UsAdjunct Professor in the Department of Integrative Structural and Computational Biology; initially associated with the laboratories of Professors Ray Stevens and Peter Kuhn, 2011-2014. The focus of the Stevens' laboratory's work is to fully characterize the crystal structure of various G-protein coupled receptors the purpose of which is to understand how these proteins respond at the molecular level to receptor agonists and antagonists. This information is used to better understand structure activity relationships to provide a complete profile of receptor-ligand interactions. The Scripps Physics in Oncology Center under the direction of Professor Kuhn is focused on advancing personalized cancer care by linking individual patient biology to clinical decision making. The focus of this work is the detection and characterization of circulating tumor cells using the laboratory's unique detection methodology to understand the genomic evolution of individual tumor cells during detection treatment and follow-up care. In 2014 became associated with Professor Ian Wilson where the focus is on the structural biology of the immune system proteins including characterization of antibodies and epitopes of HIV and Influenza in order to develop pan specific vaccines.
-
Chief Executive OfficerRev-Therapeutics 2021 - Jan 2024Rev Therapeutics is bringing new treatment options to Acute Kidney Injury patients. AKI is a leading cause of death, extra days in the ICU, and chronic kidney disease for cardiac surgery patients. RRx-002 is a patent-protected Dual-Benefit prodrug that protects renal function and prevents AKI-associated fibrosis. The drug is de-risked; it is a prodrug of a parent tested in humans for six months; it is intended for IV use in a single short treatment course.
-
Chief Executive OfficerSynbal, Inc May 2017 - Jul 2023Synbal is a San Diego-based platform technology company, that is commercializing CRISPR-based breakthrough genome editing technologies developed at the University of California, San Diego (UCSD). Our researchers have devised “Active” genetic elements with the unique property of self- replication with high efficiency and specificity (e.g. the Mutagenic Chain Reaction or MCR). “Active Genetics” overrides the natural rules of inheritance described by Mendel resulting in a novel, seamless form of inheritance. This powerful new technology platform has the potential to dramatically accelerate genetic manipulations in virtually any organism or cell. It has broad applications in a wide variety of organisms, as well as offering game-changing approaches to improve patient-specificity and efficiency/functionality of cell-therapy strategies.
-
Chairman Of The BoardAgragene, Inc. Jun 2019 - Feb 2023
-
Chairman Of The BoardSorrento Therapeutics Sep 2012 - Jan 2014San Diego, California, UsSorrento Therapeutics, Inc. is a publicly traded, clinical stage biopharmaceutical company focused primarily on the acquisition, discovery, development of proprietary therapeutics in the areas of cancer, inflammation and autoimmunity and infectious diseases. As Chairman, worked with the Board and senior management to acquire two clinical stage assets that were the basis of an up-listing on Nasdaq and a substantial increase in the valuation of the company. Finally with management enhanced the GmAb platform by acquiring an antibody drug conjugate technology company, Concortis. Resigned in January 2014 to pursue other opportunities. -
Vice President, Research & Site Director, San DiegoCelgene Sep 2003 - Jun 2011Summit, New Jersey, UsAs Vice President of Research at Celgene-San Diego (Signal Pharmaceuticals, LLC) the focus was primarily on discovering drugs and drug targets in cell signaling pathways; principally but not exclusively, kinases. The site also has carried out extensive work on ubiquitin ligases and has also carried out original research on the mechanism of action of the IMiDs. In the last seven plus years we have also produced seven clinical candidates; three of which are still in the clinic. It was also my good fortune to be the initial Project Team Leader for Otezla (Apremilast), at PDE4 inhibitor that is now approved for psoriatic arthritis and awaiting approval for psoriasis and rheumatoid arthritis. In addition, I managed the Celgene pre-clinical research alliances with Array and PTC. The Array collaboration has also led to a cancer compound which is in phase I clinical trials. Also managed all of the pre-clinical research alliances with academic/research centers world wide. -
Vice President, Drug DiscoverySyrrx 2001 - 2003As founding VP of Drug Discovery, was responsible for setting up the entire drug discovery program, hiring the senior managers in Biology and Chemistry and launching the drug discovery programs in diabetes, inflammation and cancer research. Led successful program in diabetes with a drug (Alogliptin) that is now approved in Japan, Europe and as of 2013, in the U.S. for Takeda.
-
Corporate Vice President, ResearchOsi Pharmaceuticals Sep 1999 - Sep 2001
-
Chief Scientific Officer, Vice President Of ResearchCadus Pharmaceuticals 1995 - 1999Cadus was a platform technology company using a high throughput yeast based screening technology to identify agonists and antagonists of G-protein coupled receptors. I had the responsibility to develop that technology as well as build a small molecule based drug discovery program focused around novel GPCR targets. During my tenure, we took the company public, developed three major Pharma partnerships and synthesized new classes of agonists and antagonists to the Adenosine family of GPRCs. On the basis of those programs, the assets and most of the employees became part of OSI Pharmaceuticals in 1999.
-
Distinguished Scientist And Director IibsRoche Palo Alto/ Formerly Syntex Research 1987 - 1995As Distinquished Scientist I ran a group of several post-doctoral fellows and permanent staff who worked on immune regulation and signaling pathways in the immune system in collaboration with my colleagues Drs. Bruce Devens and John Ransom. Together, we published numerous papers and abstracts and presented at national and international meetings. As the Director of the Institute of Immunology and Biological Sciences I was responsible for all of the pre-clinical research in Inflammation and Immunology world-wide. I shared these responsibilities initially with my very able colleague Dr. John Young who later took over responsibilities for what we would now call translational sciences-moving nominated compounds forward to IND. I also had the responsibility for an outstanding group of endocrinologists led by the late Dr. Brian Vickery.During this time I also had the major responsibility of building a new Nippon Syntex Research Institute of Immunology in Niihari, Japan and hiring the director and staff. During this time IIBS produced the first new drug for organ transplant rejection to approved in 23 years. This drug, now called CelCept is sold by Hoffmann LaRoche, was discovered by my colleague Dr. Anthony Allison also a Distinguished Scientist and an internationally recognized expert in Immunology. The drug annually generates over $1B dollars for Roche. In addition to CelCept, the IIBS team developed several compounds that were nominated for development in inflammation and endocrinology.
-
Distinguished ScientistSyntex 1987 - 1995See the above description
-
Associate MemberRoche Institute Of Molecular Biology 1973 - 1987The Roche Institute of Molecular Biology was founded in 1967 at Hoffmann La Roche in Nutley, NJ for the express purpose of providing a unique research environment that allowed scientists to study any topic of interest to them with the goal of furthering our general understanding of biomedical science. As the only trained immunologist, my research initially focused on the role that products of the eicosinoid pathway (prostaglandins and leukotrienes) played in regulating immunity. This involved to extensive studies in immune regulation involving T lymphocytes, B lymphocytes and macrophages. Ultimately it led to studies involving cytokine based immune regulation and the role of suppressor cells and their products in regulating immunity. This work culminated in a 1990 paper that characterized the amino terminal sequence of Soluble Immune Response Suppressor (SIRS) that was discovered in 1974 as one of the first negative regulators of immunity.
David R Webb Skills
David R Webb Education Details
-
Rutgers UniversityMicrobiology/Immunology -
California State University, FullertonGeneral
-
California State University, FullertonBiology
Frequently Asked Questions about David R Webb
What company does David R Webb work for?
David R Webb works for The Scripps Research Institute
What is David R Webb's role at the current company?
David R Webb's current role is Adjunct Professor.
What is David R Webb's email address?
David R Webb's email address is dw****@****pps.edu
What is David R Webb's direct phone number?
David R Webb's direct phone number is +191446*****
What schools did David R Webb attend?
David R Webb attended Rutgers University, California State University, Fullerton, California State University, Fullerton.
What are some of David R Webb's interests?
David R Webb has interest in History Of Science, Skiing, Education, Surfing, Wines, Management Training Of Scientists, Golf, Health.
What skills is David R Webb known for?
David R Webb has skills like Drug Discovery, Biotechnology, Immunology, Pharmaceutical Industry, Cancer, Oncology, Life Sciences, Cell Biology, Cell, Clinical Development, Drug Development, Lifesciences.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial